TScan Therapeutics, Inc. (TCRX) Cash Flow Statement

The proximity of operating cash flow to net income indicates that the company's losses are largely cash-based rather than driven by significant non-cash accounting charges. Investors should monitor this relationship, as it implies that the company lacks the non-cash cushion that might otherwise extend its runway during periods of clinical trial acceleration.

The persistent negative FCF margins, which have reached as low as -53% in previous periods, underscore the company's reliance on external financing to fund its operations. This trajectory suggests that until clinical milestones translate into more substantial, recurring cash inflows, the company will remain highly sensitive to capital market conditions.

The low absolute spending on property and equipment suggests that the company is prioritizing the outsourcing of manufacturing or utilizing existing laboratory capacity rather than building out heavy internal production facilities. This strategy appears to preserve cash for clinical trial execution, though it may warrant further investigation into the long-term scalability of its manufacturing processes.

These working capital movements appear to be driven by the episodic nature of collaboration revenue and the timing of clinical trial expenses. Investors should interpret these shifts as operational noise rather than a fundamental change in the company's ability to manage its short-term liquidity requirements.